Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Inclusion Criteria:

   - All patients with surgical stage III or IVA endometrial carcinoma per FIGO 2009
   staging criteria including clear cell and serous papillary and undifferentiated
   carcinoma

      - Surgical stage III disease includes those patients with positive adnexa,
      parametrial involvement, tumor invading the serosa, positive pelvic and/or
      para-aortic nodes, or vaginal involvement

      - Surgical stage IVA patients with bladder or bowel mucosal involvement, but no
      spread outside the pelvis

   - Patients with FIGO 2009 surgical stage I or II endometrial clear cell or serous
   carcinoma and with positive peritoneal cytology

   - Surgery must have included a hysterectomy and bilateral salpingo-oophorectomy; pelvic
   lymph node sampling and para-aortic lymph node sampling are optional

   - Patients with a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

   - White blood cell (WBC) >= 3,000/mcl

   - Absolute neutrophil count (ANC) >= 1,500/mcl

   - Platelet count >= 100,000/mcl

   - Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate
   transaminase (SGPT) =< 2.5 x upper limit of normal (ULN)

   - Alkaline phosphatase =< 2.5 times ULN

   - Bilirubin =< 1.5 times ULN

   - Creatinine =< institutional ULN

   - Patients who have met the pre-entry requirements; testing values/results must meet
   eligibility criteria

   - Patients who have signed an approved informed consent and authorization permitting
   release of personal health information

   - Entry into the study is limited to no more than 8 weeks from the date of surgery

Exclusion Criteria:

   - Patients with carcinosarcoma

   - Patients with recurrent endometrial cancer

   - Patients with residual tumor after surgery (any single site) exceeding 2 cm in maximum
   dimension

   - Patients who have had pelvic or abdominal radiation therapy

   - Patients with positive pelvic washings as the only extra-uterine disease are NOT
   eligible if the histology is other than clear cell or papillary serous carcinoma

   - Patients with a history of other invasive malignancies, with the exception of
   non-melanoma skin cancer, are excluded if there is any evidence of active malignancy
   within the last five years; patients are also excluded if their previous cancer
   treatment contraindicates this protocol therapy

   - Patients with a history of serious co-morbid illness or uncontrolled illnesses that
   would preclude protocol therapy

   - Patients with an estimated survival of less than three months

   - Patients with FIGO 2009 stage IVB endometrial cancer

   - Patients with parenchymal liver metastases

   - Patients who have received prior chemotherapy for endometrial cancer

   - Patients with a history of myocardial infarction, unstable angina, or uncontrolled
   arrhythmia within 3 months from enrollment